(Circulation. 1997;95:63-68.)
© 1997 American Heart Association, Inc.
Articles |
the Research Center and Department of Clinical Pathology, University Hospital La Fe, Valencia, Spain (M.T.S., J.V., J.A.), and the Divisions of Hematology and Medical Oncology and Departments of Medicine, Veterans Affairs Medical Center and Cornell University Medical College, New York, NY (A.J.M., M.J.B., L.B.S.).
Correspondence to Aaron J. Marcus, MD, Thrombosis Research Laboratory, Room 13028W, Department of Veterans Affairs Medical Center, 423 E 23rd St, New York, NY 10010-5050. E-mail mjbroek@mail.med.cornell.edu.
Background Aspirin effectively reduces the incidence of secondary vascular occlusive events in only 25% of patients. Low-dose aspirin as currently used blocks platelet production of prothrombotic thromboxane A2 and allows endothelial synthesis of antithrombotic prostacyclin. This regimen minimizes gastrointestinal toxicity. We previously showed that intact erythrocytes markedly enhance platelet reactivity. Therefore we investigated whether supplementation of low-dose aspirin with a single high dose at 2-week intervals could more effectively block erythrocyte promotion of platelet reactivity.
Methods and Results Effects of different aspirin regimens on erythrocyte enhancement of platelet reactivity in normal volunteers were measured with the use of an assay that evaluates both platelet activation and recruitment. After 15 days of daily ingestion of 50 mg aspirin, reactivity of platelets alone was inhibited. However, erythrocyte promotion of platelet activation and recruitment was only inhibited by
50% and persisted in the total absence of thromboxane synthesis. In contrast, if 50 mg/d aspirin was preceded by a single loading dose of 500 mg aspirin, the erythrocyte prothrombotic effect was strongly inhibited (
90%) for 2 to 3 weeks. However, over time, erythrocytes "escaped" from this inhibition, and once again became prothrombotic, even on a daily regimen of 50 mg aspirin.
Conclusions For clinical purposes, we recommend a loading dose of aspirin (500 mg), followed by daily administration of 50 mg. The loading dose should be repeated at 2-week intervals. This regimen blocks recovery of the erythrocyte capacity to promote platelet reactivity and may amplify the therapeutic potential of aspirin in cardiovascular disease.
Key Words: aspirin platelets thromboxane thrombosis erythrocytes cardiovascular diseases
This article has been cited by other articles:
![]() |
C. Patrono, C. Baigent, J. Hirsh, and G. Roth Antiplatelet Drugs: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition) Chest, June 1, 2008; 133(6_suppl): 199S - 233S. [Abstract] [Full Text] [PDF] |
||||
![]() |
J.-F. Hardy, P. de Moerloose, C. M. Samama, and Members of the Groupe d'Interet en Hemostase Perio Massive transfusion and coagulopathy: pathophysiology and implications for clinical management: [Transfusion massive et coagulopathie-: physiopathologie et implications cliniques]. Can J Anesth, June 1, 2006; 53(6_suppl): S40 - S58. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. O. Maree, R. J. Curtin, M. Dooley, R. M. Conroy, P. Crean, D. Cox, and D. J. Fitzgerald Platelet Response to Low-Dose Enteric-Coated Aspirin in Patients With Stable Cardiovascular Disease J. Am. Coll. Cardiol., October 4, 2005; 46(7): 1258 - 1263. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. T. Santos, J. Valles, M. P. Fuset, F. Perez, A. Moscardo, J. Aznar, and M. Ruano Aspirin Down-Regulation of Platelet Reactivity in Patients with Acute Coronary Syndrome: Effects of Erythrocytes. Blood (ASH Annual Meeting Abstracts), November 16, 2004; 104(11): 1865 - 1865. [Abstract] |
||||
![]() |
C. Patrono, B. Coller, G. A. FitzGerald, J. Hirsh, and G. Roth Platelet-Active Drugs: The Relationships Among Dose, Effectiveness, and Side Effects: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy Chest, September 1, 2004; 126(3_suppl): 234S - 264S. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Houel, E. Mazoyer, B. Boval, M. Kirsch, E. Vermes, L. Drouet, and D. Y. Loisance Platelet activation and aggregation profile in prolonged external ventricular support J. Thorac. Cardiovasc. Surg., August 1, 2004; 128(2): 197 - 202. [Abstract] [Full Text] [PDF] |
||||
![]() |
J.-F. Hardy, P. de Moerloose, M. Samama, and members of the Groupe d'interet en Hemostase Perio Massive transfusion and coagulopathy: pathophysiology and implications for clinical management: [Transfusion massive et coagulopathie : physiopathologie et implications cliniques] Can J Anesth, April 1, 2004; 51(4): 293 - 310. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Valles, M. T. Santos, J. Aznar, M. Martinez, A. Moscardo, M. Pinon, M. J. Broekman, and A. J. Marcus Platelet-erythrocyte interactions enhance alpha IIbbeta 3 integrin receptor activation and P-selectin expression during platelet recruitment: down-regulation by aspirin ex vivo Blood, May 13, 2002; 99(11): 3978 - 3984. [Abstract] [Full Text] [PDF] |
||||
![]() |
F Burdan Effects of prenatal exposure to combination of acetaminophen, isopropylantipyrine and caffeine on intrauterine development in rats Human and Experimental Toxicology, January 1, 2002; 21(1): 25 - 31. [Abstract] [PDF] |
||||
![]() |
C. Patrono, B. Coller, J. E. Dalen, G. A. FitzGerald, V. Fuster, M. Gent, J. Hirsh, and G. Roth Platelet-Active Drugs : The Relationships Among Dose, Effectiveness, and Side Effects Chest, January 1, 2001; 119(1_suppl): 39S - 63S. [Full Text] [PDF] |
||||
![]() |
M. T. Santos, A. Moscardo, J. Valles, M. Martinez, M. Pinon, J. Aznar, M. J. Broekman, and A. J. Marcus Participation of Tyrosine Phosphorylation in Cytoskeletal Reorganization, {alpha}IIb{beta}3 Integrin Receptor Activation, and Aspirin-Insensitive Mechanisms of Thrombin-Stimulated Human Platelets Circulation, October 17, 2000; 102(16): 1924 - 1930. [Abstract] [Full Text] [PDF] |
||||
![]() |
R J Gryglewski, W Uracz, and J Swies Unusual effects of aspirin on ticlopidine induced thrombolysis Thorax, October 1, 2000; 55(90002): 17S - 19. [Full Text] |
||||
![]() |
R. Altman, A. Scazziota, J. Rouvier, and C. Gonzalez Effects of Ticlopidine or Ticlopidine Plus Aspirin on Platelet Aggregation and ATP Release in Normal Volunteers: Why Aspirin Improves Ticlopidine Antiplatelet Activity Clinical and Applied Thrombosis/Hemostasis, October 1, 1999; 5(4): 243 - 246. [Abstract] [PDF] |
||||
![]() |
N. Li, N. H. Wallen, and P. Hjemdahl Evidence for Prothrombotic Effects of Exercise and Limited Protection by Aspirin Circulation, September 28, 1999; 100(13): 1374 - 1379. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Pratico, M. Pasin, O. P. Barry, A. Ghiselli, G. Sabatino, L. Iuliano, G. A. FitzGerald, and F. Violi Iron-Dependent Human Platelet Activation and Hydroxyl Radical Formation : Involvement of Protein Kinase C Circulation, June 22, 1999; 99(24): 3118 - 3124. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Valles, M. T. Santos, J. Aznar, A. Osa, A. Lago, J. Cosin, E. Sanchez, M. J. Broekman, and A. J. Marcus Erythrocyte Promotion of Platelet Reactivity Decreases the Effectiveness of Aspirin as an Antithrombotic Therapeutic Modality : The Effect of Low-Dose Aspirin Is Less Than Optimal in Patients With Vascular Disease Due to Prothrombotic Effects of Erythrocytes on Platelet Reactivity Circulation, February 3, 1998; 97(4): 350 - 355. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. R. Pawloski, R. V. Swaminathan, and J. S. Stamler Cell-Free and Erythrocytic S-Nitrosohemoglobin Inhibits Human Platelet Aggregation Circulation, January 27, 1998; 97(3): 263 - 267. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. S. Coller Monitoring Platelet GP IIb/IIIa Antagonist Therapy Circulation, January 13, 1998; 97(1): 5 - 9. [Full Text] [PDF] |
||||
![]() |
R. Altman, A. Scazziota, J. Rouvier, M. T. Santos, J. Valles, J. Aznar, A. J. Marcus, and M. J. Broekman Daily 50 mg or 500 mg Aspirin Does Not Affect the Cooperation of Arachidonic Acid and ADP on Platelet Aggregation • Response Circulation, January 13, 1998; 97(1): 118 - 119. [Full Text] |
||||
![]() |
B. Rocca and G. A. FitzGerald Simply Read: Erythrocytes Modulate Platelet Function: Should We Rethink the Way We Give Aspirin? Circulation, January 7, 1997; 95(1): 11 - 13. [Full Text] |
||||
|
Circulation Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 1997 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |